Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial
Open Access
- 20 October 2023
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 503-511
Abstract
Introduction: To compare responses to basal insulin glargine 300 U/ml (IGlar‐300) and 100 U/ml (IGlar‐100) in newly defined subphenotypes of type 2 diabetes. Methods: Insulin‐naive participants (n = 858) from the EDITION 3 trial were assigned to subphenotypes ‘Mild Age‐Related Diabetes (MARD)’, ‘Mild Obesity Diabetes (MOD)’, ‘Severe Insulin Resistant Diabetes (SIRD)’ and ‘Severe Insulin Deficient Diabetes (SIDD)’. Key variables were analysed at baseline and 26 weeks. Results: Participants were comprised of MOD 56.1% (n = 481), SIDD 22.1% (n = 190), MARD 18.2% (n = 156) and SIRD 3.0% (n = 26). After 26 weeks a similar decrease in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) of 16‐19 mmol/mol and 1.4‐1.7 mmol/L, respectively, occurred in MARD and MOD with both insulins. SIDD had the most elevated HbA1c and FPG (80‐83 mmol/mol/11.1‐11.4 mmol/L) and reduction in both HbA1c and FPG was greater with IGlar‐100 than with IGlar‐300 (−18 vs. −15 mmol/mol and −1.6 vs. −1.3 mmol/L, respectively; each p = .03). In SIDD, despite receiving the highest basal insulin doses, HbA1c decline (57‐60 mmol/mol/7.3‐7.6%) was suboptimal at week 26. In MOD and SIDD lower incidences with IGlar‐300 were found for level 1 nocturnal hypoglycaemia [odds ratio (OR) 0.59, 95% confidence intervals (CI) 0.36‐0.97; OR 0.49, 95% CI 0.24‐0.99]. In addition, fewer level 2 hypoglycaemia episodes occurred at any time with IGlar‐300 in SIDD (OR 0.31, 95% CI 0.13‐0.77). Conclusion: Both insulins produce comparable outcomes in type 2 diabetes subphenotypes, but in SIDD, add‐on treatment to basal insulin is required to achieve glycaemic targets.Keywords
This publication has 18 references indexed in Scilit:
- Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogsDiabetes, Obesity and Metabolism, 2020
- Hypoglycaemia risk with insulin glargine 300 U/ mL compared with glargine 100 U/ mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trialDiabetes, Obesity and Metabolism, 2020
- Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mLDiabetes, Obesity and Metabolism, 2019
- Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial dataThe Lancet Diabetes & Endocrinology, 2019
- Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 DiabetesDiabetes Care, 2018
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variablesThe Lancet Diabetes & Endocrinology, 2018
- Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2016
- Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment ResponsivenessCurrent Diabetes Reviews, 2015
- New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)Diabetes, Obesity and Metabolism, 2015
- The many faces of diabetes: a disease with increasing heterogeneityThe Lancet, 2014